Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | PSMB5 | P28074 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15469125 | 0.83 | HDAC6 (0.45) | MAPTHDAC6KDM4EPSMB5ALDH1A1 | |
| SCHEMBL15468864 | 0.83 | PTGS2 (0.39) | MAPTHDAC6KDM4ESMN1; SMN2PSMB5 | |
| SCHEMBL23553865 | 0.81 | KDM4E (0.48) | KDM4ESMN1; SMN2PSMB5ALDH1A1PSMB1 | |
| SCHEMBL9609771 | 0.80 | KAT2B (0.43) | MAPTKAT2BKDM4ESMN1; SMN2PSMB5 | |
| SCHEMBL24804775 | 0.79 | SOS1 (0.42) | — | |
| SCHEMBL16144682 | 0.78 | CASP3 (0.42) | KAT2BKDM4ESMN1; SMN2PSMB5ALDH1A1 | |
| SCHEMBL15468963 | 0.77 | MAPT (0.44) | MAPTRAB9AKAT2BKDM4ESMN1; SMN2 | |
| SCHEMBL14501877 | 0.75 | ACACB (0.40) | MAPTKDM4ESMN1; SMN2ALDH1A1PTGS2 | |
| SCHEMBL22214031 | 0.74 | PTGS2 (0.38) | MAPTKDM4ESMN1; SMN2PSMB5ALDH1A1 | |
| SCHEMBL1126792 | 0.73 | RAB9A (0.47) | MAPTRAB9AKDM4ESMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9085561-B2 | Cyclic urea- or lactam-substituted quinoxaline-type piperidines as ORL-1 modulators | PURDUE PHARMA L.P. (US) | 2015-07-21 | — | — | US | disclosed |
| US-9085561-B2 | Cyclic urea- or lactam-substituted quinoxaline-type piperidines as ORL-1 modulators | PURDUE PHARMA L.P. (US) | 2015-07-21 | — | — | US | disclosed |
| US-20140045830-A1 | CYCLIC UREA- OR LACTAM-SUBSTITUTED QUINOXALINE-TYPE PIPERIDINE COMPOUNDS AND USES THEREOF | SHIONOGI & CO., LTD. (JP) | 2014-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140045830-A1 | CYCLIC UREA- OR LACTAM-SUBSTITUTED QUINOXALINE-TYPE PIPERIDINE COMPOUNDS AND USES THEREOF | QPCT, UBXN1, NQO2 | MAPT 3443/4885RAB9A 394/4885KAT2B 1847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.